phillyvoice.com

FDA's abrupt flip‑flop on Moderna's mRNA flu shot highlights growing risks to drugmakers of investing in vaccines

The Food and Drug Administration's decision, made public on Feb. 10, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from public ...
MarketWatch

Moderna’s stock rallies as settlement of a patent dispute clears vaccine pipeline

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...
The News Journal

Moderna will pay up to $2.25B to end COVID vaccine patent fight

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...
Wall Street Journal

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Moderna MRNA-1.55%decrease; red down pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH. The vaccine maker said Tuesday that, as part ...
New York Post

Tony Danza dishes on canceled ‘Who’s the Boss’ spinoff, shelved Sebastian Maniscalco sitcom

It would have been a boss move. Tony Danza was champing at the bit to dust off his apron and reprise his iconic “Who’s the Boss” role opposite TV daughter Alyssa Milano in a spinoff about the pair ...
Wall Street Journal

The Moderna Flu-Shot Drama

The Food and Drug Administration agreed Wednesday to review Moderna’s application to make a new seasonal flu shot available, after initially refusing to do so. The back-and-forth reveals increased ...
Reuters

BioNTech sues Moderna for patent infringement over COVID shots

Feb 19 (Reuters) - German biopharmaceutical company BioNTech (22UAy.DE), opens new tab sued Moderna (MRNA.O), opens new tab in Delaware federal court on Thursday, alleging that Moderna's COVID-19 shot ...
The Conversation

FDA’s abrupt flip‑flop on Moderna’s mRNA flu shot highlights growing risks to drug‑makers of investing in vaccines

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...
Boston Herald

Moderna says the FDA will consider its new flu shot after resolving a public dispute

WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of ...
The Motley Fool

Why Moderna Stock Just Popped

The FDA had previously rejected Moderna's application, refusing even to review it after concluding Moderna hadn't done sufficient safety testing. Now, Moderna is promising to do additional testing to ...
CBS News

Moderna says FDA will now review its new flu vaccine, reversing earlier decision

The U.S. Food and Drug Administration has reversed an earlier decision and said it will review drugmaker Moderna's application for approval of a seasonal flu vaccine, the company said in a statement ...